# LITESPARK-004 (NCT03401788)

> A Phase 2 Study of Belzutifan (PT2977, MK-6482) for the Treatment of Von Hippel Lindau (VHL) Disease-Associated Renal Cell Carcinoma (RCC) (MK-6482-004)

No report yet. It can be ordered.

- Drugs tested: belzutifan
- Indication: von Hippel-Lindau disease-associated renal cell carcinoma

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT03401788
- Phase: PHASE2
- Status: ACTIVE_NOT_RECRUITING
- Sponsor: Peloton Therapeutics, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
- Conditions: VHL - Von Hippel-Lindau Syndrome; VHL Gene Mutation; VHL Syndrome; VHL Gene Inactivation; VHL-Associated Renal Cell Carcinoma; VHL-Associated Clear Cell Renal Cell Carcinoma
- Interventions: Belzutifan
- Enrollment: 50
- Primary outcome: Objective Response Rate (ORR) in VHL Disease-Associated RCC Tumors

## Indexed commentary on LITESPARK-004 so far

Podcasts, YouTube videos and X posts we have indexed that name the trial. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.

- X threads: 27
- YouTube: 10
- Podcasts: 5

## Order

Deep, $1,950, price fixed at order: https://www.erudio.com/contact?report=litespark-004-nct03401788

## Free preview

POST https://www.erudio.com/api/trial-requests with {"nct_id": "NCT03401788", "email": "<work email>"}; the inbox owner confirms by the emailed link.